Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5-Reference-Cited by-同舟云学术

Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5

Published:2020-05-08 Issue:5 Volume:15 Page:e0231892
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Latuszek Adrianna,Liu Yashu,Olsen Olav^ORCID,Foster Randi,Cao Marc,Lovric Irena,Yuan Ming,Liu Nina,Chen Henry,Zhang Qian,Xiao Hui,Springer Carola,Ehrlich George,Kamat Vishal,Rafique Ashique^ORCID,Hu Ying,Krueger Pamela,Huang Tammy,Poueymirou William,Babb Robert,Rosconi Michael P.,Retter Marc W.,Chen Gang,Morton Lori,Zambrowicz Brian,Cao Jingtai,Romano Carmelo,Olson William C.

Funder

Regeneron Pharmaceuticals

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference26 articles.

1. Complement, a target for therapy in inflammatory and degenerative diseases;BP Morgan;Nat Rev Drug Discov,2015

2. Complement. First of two parts;MJ Walport;N Engl J Med,2001

3. Complement. Second of two parts;MJ Walport;N Engl J Med,2001

4. Role of C5a in inflammatory responses;RF Guo;Annu Rev Immunol,2005

5. Complement component 5a (C5a).;HD Manthey;Int J Biochem Cell Biol,2009

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Complement‐targeted therapeutics: Are we there yet, or just getting started?;European Journal of Immunology;2024-09-12

2. Pharmacotherapy for CD55 deficiency with CHAPLE disease: how close are we to a cure?;Expert Opinion on Pharmacotherapy;2024-07-23

3. Targeted treatments for immune dysregulation in inborn errors of immunity;Exploration of Immunology;2024-04-23

4. Pozelimab, a human monoclonal immunoglobulin for the treatment of CHAPLE disease;Journal of Basic and Clinical Physiology and Pharmacology;2024-04-11

5. Structure and function of therapeutic antibodies approved by the US FDA in 2023;Antibody Therapeutics;2024-03-19